Assessment of the biopotency of follitropin alfa and lutropin alfa combined in one injection: a comparative trial in Sprague-Dawley rats
Open Access
- 22 July 2008
- journal article
- research article
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 6 (1) , 31
Abstract
Background: The current study was designed to determine if follitropin alfa (recombinant human follicle-stimulating hormone; r-hFSH) and lutropin alfa (recombinant human luteinizing hormone; r-hLH) biopotencies were unchanged by reconstituting in sterile water for injection and mixing prior to injection. Methods: The biopotencies of r-hFSH and r-hLH were determined following injection of female Sprague-Dawley rats with a mixture of follitropin alfa revised formulation female (RFF) and lutropin alfa (1:1, r-hFSH:r-hLH). Biopotencies of follitropin alfa RFF and lutropin alfa were measured using ovarian weight and ascorbic acid depletion assays, respectively, and compared with a reference standard. Stock mixtures of follitropin alfa RFF and lutropin alfa (1:1) were prepared within 1 h prior to each respective assay's injection and stored at 6 +/- 2°C. Separate low dose (follitropin alfa RFF 1.5 IU/rat, lutropin alfa 2 IU/rat) and high dose (follitropin alfa RFF 3 IU/rat, lutropin alfa 8 IU/rat) treatments were prepared from stock mixtures or individual solutions by diluting with 0.22% bovine serum albumin saline solution and injected within 1 h of preparation. The main outcome measures were ovarian weight and ovarian ascorbic acid depletion. Results: FSH bioactivities were similar (p > 0.10) between the individual follitropin alfa RFF test solution (84.2 IU) and follitropin alfa RFF/lutropin alfa (87.6 IU) mixtures prepared within 1 h of injection and stored at 6 +/- 2°C. LH bioactivities were similar (p > 0.10) between lutropin alfa (94.7 IU) test solution and lutropin alfa/follitropin alfa RFF (85.3 IU) mixtures prepared within 1 h of injection and stored at 6 +/- 2°C for not more than 1 h prior to injection. Conclusion: Mixing follitropin alfa RFF and lutropin alfa did not alter the bioactivity of either FSH or LH.Keywords
This publication has 18 references indexed in Scilit:
- Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trialHuman Reproduction, 2005
- Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniquesFertility and Sterility, 2004
- Historical perspectives in gonadotrophin therapyHuman Reproduction Update, 2004
- Why do couples discontinue in vitro fertilization treatment? a cohort studyFertility and Sterility, 2004
- The fourth International Standard for Human Urinary FSH and LH: specificities of LH seminal vesicle weight gain assays in the collaborative study differ between laboratoriesJournal of Endocrinology, 2001
- In vitro fertilization cycle medication administration: combining follicle-stimulating hormone with GnRH-agonist in a single injection.Fertility and Sterility, 2001
- Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormoneFertility and Sterility, 1998
- Genetic engineering of human FSH (Gonal-F(R))Human Reproduction Update, 1996
- A comparison of preparations of highly purified human pituitary luteinizing hormone: differences in the luteinizing hormone potencies as determined by in vivo bioassays, in vitro bioassay and immunoassayEuropean Journal of Endocrinology, 1982
- Pituitary Control of Ovarian Function — Concepts Derived from Gonadotrophin TherapyAustralian and New Zealand Journal of Obstetrics and Gynaecology, 1978